2022-08 | The company has been approved for public issuance of shares and the stock symbol is「6917」 |
2022-07 | Complete the seventh round financing July 2022. The capital increased to NTD 348M |
2022-07 | APC201 sent to Australia and Taiwan for planned to enter Phase I/II clinical trials |
2022-02 | Complete the sixth round financing in February 2022. The capital increased to NTD 284 M |
2021-03 | LALP cream officially entered the hospital system for sales |
2021-02 | Andros Pharmaceuticals passed TFDA follow-up inspection of GMP. |
2020-11 | " Development of Topical New Dosage Form of Local Anesthetic Complex" project has received R&D subsidies from the Ministry of Ec |
2020-10 | Signed a licensing cooperation contract of LALP cream with Hong Kong Pharmaceuticals to develop the local anesthetics market in |
2020-03 | APC101 completed the phase IIa clinical trial report in Australia. |
2018-10 | President Ae-June Wang received the Excellence in Management Award at the 7th Woman Elite Entrepreneurs Competition. |
2018-06 | Andros Pharmaceuticals received Taiwan FDA licenses for 2% and 5% iMinos Solution (site change) |
2018-02 | Andros Pharmaceuticals passed TFDA audit inspection of GMP and GDP. |
2017-04 | Andros Pharmaceuticals received Taiwan FDA license for LALP Cream (site change) |
2016-12 | Andros Pharmaceuticals received innovative product award from Hsinchu Science Park on December 2016 |
2016-10 | Andros Pharmaceuticals won the excellent execution award of SBIR program on October 2016 |
2016-10 | The Commercial Times reported Andros won the award of SBIR program |
2016-03 | Andros Pharmaceuticals got the certificate of PIC/S GMP for adding liquid dosage form. |
2015-09 | Andros Pharmaceuticals got the certificate of PIC/S GMP. |
2015-03 | Complete the fifth round financing in March 2015. The capital increased to NTD 243M. |
2015-02 | Complete the forth round financing in February 2015. The capital increased to NTD 213M. |
2014-07 | "The preclinical study of the topical anesthetic new dosage form" project has received the SBIR grant from MOEA. |
2014-05 | "The subsequent project of topical delivery system development" received R&D subsidy from Taipei city government. |
2014-02 | The Commercial Times reported the recent development of Andros Pharmaceuticals and praised our performance. |
2013-12 | Andros Pharmaceuticals is recognized by Ministry of Economic Affairs as a “Biotech and New Pharmaceuticals Company”. |
2013-07 | Complete the third round financing in July 2013. The capital increased to NTD 150M. |
2013-06 | The newest job opportunities are available now |
2013-02 | "The development of topical delivery system" project received research and development subsidy from Taipei city government. |
2013-01 | The Commercial Times reported Andros Pharmaceuticals entered Hsinchu Biomedical Science Park. |
2013-01 | Andros Pharmaceuticals has relocated to Hsinchu Biomedical Science Park on 2nd Jan, 2013. |
2012-10 | Complete the second round of financing in October 2012. The capital increased to NTD 100M. |
2011-06 | Received NTD 12M of SBIR grant from MOEA for the development of “topical anesthetic new dosage form” project. |
2011-05 | Opening of the Hsinchu biomedical science park research building attended by President Ma Ying-Jeou. |
2010-11 | Approved by Hsinchu biomedical science park for relocation in late-2012. |